dc.contributor.author |
Lukhwareni, Azwidowi
|
|
dc.contributor.author |
Gededzha, Maemu Petronella
|
|
dc.contributor.author |
Amponsah-Dacosta, Edina
|
|
dc.contributor.author |
Blackard, Jason T.
|
|
dc.contributor.author |
Burnett, Rosemary J.
|
|
dc.contributor.author |
Selabe, Selokela Gloria
|
|
dc.contributor.author |
Kyaw, Thanda
|
|
dc.contributor.author |
Mphahlele, M. Jeffrey
|
|
dc.date.accessioned |
2021-02-15T09:39:41Z |
|
dc.date.available |
2021-02-15T09:39:41Z |
|
dc.date.issued |
2020-06 |
|
dc.description.abstract |
This prospective study investigated the impact of lamivudine-containing antiretroviral
therapy (ART) on HIV-positive patients in South Africa with baseline hepatitis B virus (HBV)
infection. Follow-up samples from 56 HBV/HIV co-infected patients, 25 with occult HBV infection
(OBI) and 31 with chronic HBV infection (CHB), were available for analysis. HBV viral loads were
quantified at 6, 12, 18, and 24 months post-ART initiation by the COBAS TaqMan HBV Test 48
assay, and the HBV polymerase gene was amplified with an in-house nested polymerase chain
reaction assay. During 24 months of lamivudine-based ART, 6 of 8 (75%) OBI and 4 of 6 (67%) CHB
patients achieved undetectable levels of HBV DNA, while 2 patients had persistent HBV DNA levels
2 105 despite lamivudine-based ART for 24 months. HIV viremia was undetectable in all patients
at 12 months, suggesting high adherence to ART. Several lamivudine-associated HBV resistance
mutations, including L180M, A181T, M204I, and M204V, were observed. Sequence analysis also
revealed a rare genotype G infection. While resource-limited settings may use lamivudine-based
ART because of availability and low cost, antivirals with dual therapy against HBV and HIV (e.g.,
lamivudine and tenofovir) should always be recommended with the regular monitoring of HBV
viremia levels. |
en_ZA |
dc.description.department |
Medical Virology |
en_ZA |
dc.description.librarian |
am2021 |
en_ZA |
dc.description.sponsorship |
The South African National Research Foundation, Poliomyelitis Research Foundation, Stella and Paul Lowenstein Trust, and Canon and Collins scholarship. |
en_ZA |
dc.description.uri |
http://www.mdpi.com/journal/viruses |
en_ZA |
dc.identifier.citation |
Lukhwareni, A., Gedezha, M.P., Amponsah-Dacosta, E. et al. 2020, 'Impact of lamivudine-based antiretroviral treatment on hepatitis B viremia in HIV-coinfected South Africans', Vruses, vol. 12, no. 6, art. 634, pp. 1-13. |
en_ZA |
dc.identifier.issn |
1999-4915 (online) |
|
dc.identifier.other |
10.3390/v12060634 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/78613 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
MDPI Publishing |
en_ZA |
dc.rights |
© 2020 by the authors.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. |
en_ZA |
dc.subject |
Lamivudine |
en_ZA |
dc.subject |
Antiretroviral therapy (ART) |
en_ZA |
dc.subject |
Hepatitis B virus (HBV) |
en_ZA |
dc.subject |
HIV coinfection |
en_ZA |
dc.subject |
Human immunodeficiency virus (HIV) |
en_ZA |
dc.title |
Impact of lamivudine-based antiretroviral treatment on hepatitis B viremia in HIV-coinfected South Africans |
en_ZA |
dc.type |
Article |
en_ZA |